258 related articles for article (PubMed ID: 23551100)
1. Role of PI3K/Akt and mTOR complexes in Th17 cell differentiation.
Nagai S; Kurebayashi Y; Koyasu S
Ann N Y Acad Sci; 2013 Mar; 1280():30-4. PubMed ID: 23551100
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in understanding the molecular mechanisms of the development and function of Th17 cells.
Kurebayashi Y; Nagai S; Ikejiri A; Koyasu S
Genes Cells; 2013 Apr; 18(4):247-65. PubMed ID: 23383714
[TBL] [Abstract][Full Text] [Related]
3. Key molecules in the differentiation and commitment program of T helper 17 (Th17) cells up-to-date.
Hemdan NY; Birkenmeier G; Wichmann G
Immunol Lett; 2012 Dec; 148(2):97-109. PubMed ID: 23036716
[TBL] [Abstract][Full Text] [Related]
4. ERK1/2-dependent activation of mTOR/mTORC1/p70S6K regulates thrombin-induced RPE cell proliferation.
Parrales A; López E; Lee-Rivera I; López-Colomé AM
Cell Signal; 2013 Apr; 25(4):829-38. PubMed ID: 23291002
[TBL] [Abstract][Full Text] [Related]
5. IL-22 induced cell proliferation is regulated by PI3K/Akt/mTOR signaling cascade.
Mitra A; Raychaudhuri SK; Raychaudhuri SP
Cytokine; 2012 Oct; 60(1):38-42. PubMed ID: 22840496
[TBL] [Abstract][Full Text] [Related]
6. Intracellular reactive oxygen species are essential for PI3K/Akt/mTOR-dependent IL-7-mediated viability of T-cell acute lymphoblastic leukemia cells.
Silva A; Gírio A; Cebola I; Santos CI; Antunes F; Barata JT
Leukemia; 2011 Jun; 25(6):960-7. PubMed ID: 21455214
[TBL] [Abstract][Full Text] [Related]
7. PI3K-Akt-mTORC1-S6K1/2 axis controls Th17 differentiation by regulating Gfi1 expression and nuclear translocation of RORγ.
Kurebayashi Y; Nagai S; Ikejiri A; Ohtani M; Ichiyama K; Baba Y; Yamada T; Egami S; Hoshii T; Hirao A; Matsuda S; Koyasu S
Cell Rep; 2012 Apr; 1(4):360-73. PubMed ID: 22832227
[TBL] [Abstract][Full Text] [Related]
8. Activation of TGF-β-induced non-Smad signaling pathways during Th17 differentiation.
Hasan M; Neumann B; Haupeltshofer S; Stahlke S; Fantini MC; Angstwurm K; Bogdahn U; Kleiter I
Immunol Cell Biol; 2015 Aug; 93(7):662-72. PubMed ID: 25823994
[TBL] [Abstract][Full Text] [Related]
9. mTORC1 signaling and IL-17 expression: Defining pathways and possible therapeutic targets.
Ren W; Yin J; Duan J; Liu G; Tan B; Yang G; Wu G; Bazer FW; Peng Y; Yin Y
Eur J Immunol; 2016 Feb; 46(2):291-9. PubMed ID: 26558536
[TBL] [Abstract][Full Text] [Related]
10. Atrial natriuretic peptide suppresses Th17 development through regulation of cGMP-dependent protein kinase and PI3K-Akt signaling pathways.
Ma L; Li J; Wang G; Gong S; Zhang L; Li K; Ji X; Liu Y; Chen P; Xiang X
Regul Pept; 2013 Feb; 181():9-16. PubMed ID: 23327998
[TBL] [Abstract][Full Text] [Related]
11. The imbalance of Treg/Th17 cells induced by perinatal bisphenol A exposure is associated with activation of the PI3K/Akt/mTOR signaling pathway in male offspring mice.
Gao L; Dong Y; Lin R; Meng Y; Wu F; Jia L
Food Chem Toxicol; 2020 Mar; 137():111177. PubMed ID: 32028014
[TBL] [Abstract][Full Text] [Related]
12. [Recent studies on PI3K/AKT/mTOR signaling pathway in hematopoietic stem cells].
Zhang YC; Cheng T; Yuan WP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):245-9. PubMed ID: 23484729
[TBL] [Abstract][Full Text] [Related]
13. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.
Yu K; Shi C; Toral-Barza L; Lucas J; Shor B; Kim JE; Zhang WG; Mahoney R; Gaydos C; Tardio L; Kim SK; Conant R; Curran K; Kaplan J; Verheijen J; Ayral-Kaloustian S; Mansour TS; Abraham RT; Zask A; Gibbons JJ
Cancer Res; 2010 Jan; 70(2):621-31. PubMed ID: 20068177
[TBL] [Abstract][Full Text] [Related]
14. PI3K-p110-alpha-subtype signalling mediates survival, proliferation and neurogenesis of cortical progenitor cells via activation of mTORC2.
Wahane SD; Hellbach N; Prentzell MT; Weise SC; Vezzali R; Kreutz C; Timmer J; Krieglstein K; Thedieck K; Vogel T
J Neurochem; 2014 Jul; 130(2):255-67. PubMed ID: 24645666
[TBL] [Abstract][Full Text] [Related]
15. Mammalian target of rapamycin complex 2 (mTORC2) regulates LPS-induced expression of IL-12 and IL-23 in human dendritic cells.
Wei WC; Liu CP; Yang WC; Shyur LF; Sheu JH; Chen SS; Yang NS
J Leukoc Biol; 2015 Jun; 97(6):1071-80. PubMed ID: 25877925
[TBL] [Abstract][Full Text] [Related]
16. PLC and PI3K/Akt/mTOR signalling in disease and cancer.
Follo MY; Manzoli L; Poli A; McCubrey JA; Cocco L
Adv Biol Regul; 2015 Jan; 57():10-6. PubMed ID: 25482988
[TBL] [Abstract][Full Text] [Related]
17. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.
Wysocki PJ
Expert Rev Mol Diagn; 2009 Apr; 9(3):231-41. PubMed ID: 19379082
[TBL] [Abstract][Full Text] [Related]
18. The PI3K/Akt/mTOR signaling pathway mediates insulin-like growth factor 1-induced E-cadherin down-regulation and cell proliferation in ovarian cancer cells.
Lau MT; Leung PC
Cancer Lett; 2012 Dec; 326(2):191-8. PubMed ID: 22922215
[TBL] [Abstract][Full Text] [Related]
19. BCAP links IL-1R to the PI3K-mTOR pathway and regulates pathogenic Th17 cell differentiation.
Deason K; Troutman TD; Jain A; Challa DK; Mandraju R; Brewer T; Ward ES; Pasare C
J Exp Med; 2018 Sep; 215(9):2413-2428. PubMed ID: 30093533
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
